Bristol-Myers Squibb To Present New Data From Its Immuno-Oncology Clinical Development Programs At 16th World Conference On Lung Cancer

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced data from its Immuno-Oncology clinical development programs to be presented at the 16th World Conference on Lung Cancer (WCLC) in Denver, CO from September 6-9. The company is presenting Opdivo (nivolumab) data in a broad set of patients with lung cancer, across histologies and treatment settings.

Help employers find you! Check out all the jobs and post your resume.